Ginsenoside F1 (Synonyms: GF1, Panaxoside A Progenin) |
Catalog No.GN10032
One-Click Copy Product Info
|
Ginsenoside F1은 인삼에서 추출된 이차 대사 산물이며, 인삼사포닌 Rg1의 탈당 유도체이다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 53963-43-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ginsenoside F1은 인삼에서 추출된 이차 대사 산물이며, 인삼사포닌 Rg1의 탈당 유도체이다. Ginsenoside F1은 인슐린 유사 성장 인자-1에 의존적인 메커니즘을 통해NK 세포의 세포 독성 활성을 증진한다[2]. Ginsenoside F1은 주로 암과 염증을 치료할 때 사용된다[3].
인간 탯줄 정맥 내피세포(HUVECs)에서 Ginsenoside F1(20, 40μM; 24시간)은 HUVECs의 증식, 이동 및 침입을 촉진한다[4]. HEK293 세포에서 Ginsenoside F1(50, 100, 200µg/mL; 4시간)은 B16 흑색종 세포의 증식을 최대 60%까지 현저하게 억제한다[5]. HaCaT 세포에서 Ginsenoside F1(1, 5, 10, 50μM; 24시간)은 HaCaT 세포를 UVB 유도 세포 사멸로부터 보호한다[6]. SH-SY5Y 세포에서 Ginsenoside F1(2.5, 5, 10μM; 24시간)은 신경 세포에서 Aβ1–42 유도 세포 독성을 감소시킨다[7].
알츠하이머병(AD) 모델 쥐에서 Ginsenoside F1(20mg/kg; 경구 투여; 8주)은 APPswe/PSEN1dE9(APP/PS1) 이중 형질전환 AD 모델 생쥐의 기억 기능을 향상시킨다[8]. 고지방 식이로 유도된 ApoE-/- 동맥 경화증 쥐에서 Ginsenoside F1(50mg/kg; 경구 투여; 8주)은 A20 매개체를 통해 NF-kB 신호 전달을 억제해서 내피 세포 염증 손상을 개선하고 쥐의 동맥 경화를 예방한다[9]. ob/ob 쥐에서 Ginsenoside F1(60mg/kg; 경구 투여; 5주) 투여는 열 발생을 증가시켜 혈당과 지질 수치를 낮춘다[10].
References:
[1]. Meragelman TL, Renteria BS, Silva GL, et al. Modified secoiridoid from Acicarpha tribuloides and inhibition of nitric oxide production in LPS-activated macrophages. Phytochemistry. 2006 Jul 1; 67(14): 1534-1538.
[2]. Kwon HJ, Lee H, Choi GE, et al. Ginsenoside F1 promotes cytotoxic activity of NK cells via insulin-like growth factor-1-dependent mechanism. Frontiers in Immunology. 2018 Nov 28; 9: 2785.
[3]. Li J, Li F, Jin D. Ginsenosides are promising medicine for tumor and inflammation: A review. The American journal of Chinese medicine. 2023 Apr 17; 51(04): 883-908.
[4]. Zhang J, Liu M, Huang M, et al. Ginsenoside F1 promotes angiogenesis by activating the IGF-1/IGF1R pathway. Pharmacological Research. 2019 Jun 1; 144: 292-305.
[5]. Yoo DS, Rho HS, Lee YG, et al. Ginsenoside F1 modulates cellular responses of skin melanoma cells. Journal of Ginseng Research. 2011; 35(1): 86-91.
[6]. Lee EH, Cho SY, Kim SJ, et al. Ginsenoside F1 protects human HaCaT keratinocytes from ultraviolet-B-induced apoptosis by maintaining constant levels of Bcl-2. Journal of investigative dermatology. 2003 Sep 1; 121(3): 607-613.
[7]. Yun YJ, Park BH, Hou J, et al. Ginsenoside F1 protects the brain against amyloid beta-induced toxicity by regulating IDE and NEP. Life. 2022 Jan 1; 12(1): 58.
[8]. Han J, Oh JP, Yoo M, et al. Minor ginsenoside F1 improves memory in APP/PS1 mice. Molecular Brain. 2019 Dec; 12: 1-8.
[9]. Qin M, Luo Y, Lu S, et al. Ginsenoside F1 ameliorates endothelial cell inflammatory injury and prevents atherosclerosis in mice through A20-mediated suppression of NF-kB signaling. Frontiers in Pharmacology. 2017 Dec 22; 8: 953.
[10]. Meng Y, Li W, Hu C, et al. Ginsenoside F1 administration promotes UCP1-dependent fat browning and ameliorates obesity-associated insulin resistance. Food Science and Human Wellness. 2023 Nov 1; 12(6): 2061-2072.
| 세포 실험 [1]: | |
세포 라인 | 인간 탯줄 정맥 내피세포(HUVECs) |
제조 방법 | Ginsenoside F1이HUVECs의 증식에 미치는 영향은 EdU 세포 증식 분석을 통해 측정되었습니다. 간략하게 HUVECs나HBMECs를 96웰 판에 3×10³개의 세포/웰로 심은 다음 밤새 배양을 진행했습니다. 이 후에 EdU 세포 증식 키트의 표준 프로토콜에 따라 Ginsenoside F1(20과 40μM)으로 24시간 동안 처리했습니다. |
반응 조건 | 20, 40μM; 24 시간 동안 |
응용 분야 | Ginsenoside F1은HUVECs의 증식, 이동 및 침입을 촉진합니다. |
| 동물 실험 [2]: | |
동물 모형 | 알츠하이머병 (AD) 모델 쥐 |
제조 방법 | 알츠하이머병(AD)에 대한 Ginsenoside F1의 효과를 테스트하기 위해 젤라틴 기반 젤리를 통해 20mg/kg/일의 용량으로 경구 투여되었습니다. 1일 분량의 젤리에 대해 0.45mL의 20% Splenda 용액에 0.6mg의 Ginsenoside F1을 녹였습니다. Ginsenoside F1 용액은 24웰 판에서 14% 젤라틴, 20% Splenda 용액과 0.15mL 초콜릿 향료와 더 혼합되었습니다. 젤리 한 조각(약 1.9mg)이 제공되었고 젤리의 완전한 섭취는 매일 확인되었습니다. |
제형 | 20mg/kg; po; 8 주 동안 |
응용 분야 | Ginsenoside F1은 APPswe/PSEN1dE9(APP/PS1) 이중AD 모델 쥐의 기억 기능을 향상시킵니다. |
References: | |
| Cas No. | 53963-43-2 | SDF | |
| Synonyms | GF1, Panaxoside A Progenin | ||
| Chemical Name | (2R,3S,4R,5R,6S)-2-(hydroxymethyl)-6-[(2R)-6-methyl-2-[(6R,10R,12S,13R,14R,17S)-3,6,12-trihydroxy-4,4,10,14,17-pentamethyl-2,3,5,6,7,8,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]hept-5-en-2-yl]oxyoxane-3,4,5-triol | ||
| Canonical SMILES | CC(=CCCC(C)(C1(CCC2(C1C(CC3C2CC(C4C3(CCC(C4(C)C)O)C)O)O)C)C)OC5C(C(C(C(O5)CO)O)O)O)C | ||
| Formula | C36H62O9 | M.Wt | 638.87 |
| Solubility | ≥ 31.95mg/mL in DMSO with ultrasonic | Storage | Store at 2-8°C,protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5653 mL | 7.8263 mL | 15.6526 mL |
| 5 mM | 313.1 μL | 1.5653 mL | 3.1305 mL |
| 10 mM | 156.5 μL | 782.6 μL | 1.5653 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)